Zdemir Ayşegül, Kiliç Koray, Ozdemir Hakan, Yücel Cem, Andaç Sebnem, Colak Meriç
Department of Radiology, University Hospital of Gazi, Ankara, Turkey.
J Ultrasound Med. 2004 Feb;23(2):183-95; quiz 196-7. doi: 10.7863/jum.2004.23.2.183.
To evaluate the efficacy of contrast-enhanced power Doppler sonography in the differential diagnosis of breast lesions after a mammography-gray scale sonography combination.
Sixty-eight patients with 69 breast masses underwent power Doppler sonography before and after intravenous injection of a contrast agent. The lesions were diagnosed as "highly suggestive of malignancy" (category 5; n = 32), "suspicious" (category 4; n = 21), and "probably benign" (category 3; n = 16) by mammography and gray scale sonography, modeled on the American College of Radiology Breast Imaging Reporting and Data System classification. Power Doppler findings did not affect patient treatment. The authors subjectively evaluated the estimated area of vascularity, degree of enhancement following contrast agent administration, morphologic features, and distribution of vessels within the lesions.
The final diagnoses were malignant in 28 lesions and benign in 41. Significant enhancement after contrast agent injection was detected in both the malignant and benign groups. Only 2 criteria, estimated area of vascularity and degree of enhancement following contrast agent administration, proved to be significant diagnostic determinants for contrast-enhanced power Doppler sonography (P < .001; interobserver agreements, 74.4 and 77.8, respectively). Contrast-enhanced power Doppler sonography provided a higher specificity, positive predictive value, and negative predictive value than power Doppler sonography but a lower sensitivity and negative predictive value than mammography-gray scale sonography. Only in the category 4 lesions could the combination of mammography-gray scale sonography and contrast-enhanced power Doppler sonography accomplish a higher specificity (71%) and positive predictive value (70%) than mammography-gray scale sonography (39% and 53%, respectively).
Power Doppler and contrast-enhanced power Doppler sonography cannot be recommended as confirmatory tests in Breast Imaging Reporting and Data System category 3 and category 5 lesions. Although contrast-enhanced power Doppler sonography may help reduce unnecessary biopsies in Breast Imaging Reporting and Data System category 4 lesions, recommendation of its use has many drawbacks, such as imperfectly established criteria, lack of absolute certainty, and high cost.
评估在乳腺钼靶-灰阶超声联合检查后,对比增强功率多普勒超声在乳腺病变鉴别诊断中的效能。
68例患有69个乳腺肿块的患者在静脉注射造影剂前后接受了功率多普勒超声检查。根据美国放射学会乳腺影像报告和数据系统分类,通过乳腺钼靶和灰阶超声将病变诊断为“高度怀疑恶性”(5类;n = 32)、“可疑”(4类;n = 21)和“可能良性”(3类;n = 16)。功率多普勒检查结果不影响患者治疗。作者主观评估了病变内血管的估计面积、造影剂注射后的增强程度、形态特征和血管分布。
最终诊断为恶性病变28个,良性病变41个。恶性组和良性组在注射造影剂后均检测到明显增强。只有血管估计面积和造影剂注射后的增强程度这两个标准被证明是对比增强功率多普勒超声的重要诊断决定因素(P <.001;观察者间一致性分别为74.4和77.8)。对比增强功率多普勒超声比功率多普勒超声具有更高的特异性、阳性预测值和阴性预测值,但比乳腺钼靶-灰阶超声联合检查具有更低的敏感性和阴性预测值。只有在4类病变中,乳腺钼靶-灰阶超声联合对比增强功率多普勒超声才能实现比乳腺钼靶-灰阶超声联合检查更高的特异性(71%)和阳性预测值(70%)(分别为39%和53%)。
在乳腺影像报告和数据系统3类和5类病变中,不推荐将功率多普勒和对比增强功率多普勒超声作为确诊检查。虽然对比增强功率多普勒超声可能有助于减少乳腺影像报告和数据系统4类病变中不必要的活检,但推荐使用它存在许多缺点,如标准不完善、缺乏绝对确定性和成本高。